{"id":"b1638aac365d","type":"article","url":"https://hartvaat.nl/2025/01/01/stijging-van-serum-transthyretine-na-tafamidis-voorspelt-betere-overleving-bij-a/","title":"Stijging van serum-transthyretine na tafamidis voorspelt betere overleving bij ATTR-cardiomyopathie","title_en":"Increase in Serum Transthyretin After Tafamidis Is Associated With Improved Survival in Transthyretin Amyloid Cardiomyopathy","category":"hartfalen","category_label":"Hartfalen","professions":["apotheker","cardioloog"],"tags":[],"journal":"JACC","doi":"https://www.sciencedirect.com/science/article/pii/S0735109726000574?dgcid=rss_sd_all","source_url":"https://doi.org/https://www.sciencedirect.com/science/article/pii/S0735109726000574?dgcid=rss_sd_all","authors":["Bilal Ansari","Nelson I. Barrera","Dimitrios Bampatsias","Sergio Teruya","Alfonsina Mirabal-Santos","Stephen Helmke","Karan Wats","Yevgeniy Brailovsky","Mathew S. Maurer"],"significance":7,"published":"2026-03-01","source_date":"2025-01-01","image":"","kennis":[],"congress":"","summary_en":"This study showed that an increase in serum transthyretin after starting tafamidis is associated with improved survival in ATTR cardiomyopathy, establishing a potential on-treatment biomarker for monitoring therapeutic response.","created":"2026-07-03T10:25:47Z","updated":"2026-07-03T13:25:10Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"Onderzoek of een stijging van serum-transthyretine na het starten van tafamidis geassocieerd is met verbeterde overleving bij transthyretine-amyloïd cardiomyopathie.","abstract_original":"Publication date: Available online 18 February 2026Source: JACC"}